The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.
Nanocarriers for delivery of platinum anticancer drugs
Open accessAbstract
Platinum based anticancer drugs have revolutionized cancer chemotherapy, and continue to be in widespread clinical use especially for management of tumors of the ovary, testes, and the head and neck. However, several dose limiting toxicities associated with platinum drug use, partial anti-tumor response in most patients, development of drug resistance, tumor relapse, and many other challenges have severely limited the patient quality of life. These limitations have motivated an extensive research effort towards development of new strategies for improving platinum therapy. Nanocarrier-based delivery of platinum compounds is one such area of intense research effort beginning to provide encouraging preclinical and clinical results and may allow the development of the next generation of platinum chemotherapy. This review highlights current understanding on the pharmacology and limitations of platinum compounds in clinical use, and provides a comprehensive analysis of various platinum–polymer complexes, micelles, dendrimers, liposomes and other nanoparticles currently under investigation for delivery of platinum drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–214 of 214
Bellis, E., Hajba, L., Kovács, B., Sándor, K., Kollár, L., & Kokotos, G. (2006) · Journal of Biochemical and Biophysical Methods · doi:10.1016/j.jbbm.2006.02.006 · Cited by 29
Jin, W., Xu, P., Zhan, Y., Shen, Y., Kirk, E. A. V., Alexander, B. M., Murdoch, W. J., Liu, L., & Isaak, D. D. (2007) · Drug Delivery · doi:10.1080/10717540601036856 · Cited by 29
Cisplatin differently affects amino terminal and carboxyl terminal domains of HSP90
Ishida, R., Takaoka, Y., Yamamoto, S., Miyazaki, T., Otaka, M., Watanabe, S., Komatsuda, A., Wakui, H., Sawada, K., KUBOTA, H. Y., et al. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.029 · Cited by 27
Macromolecular Antiproliferative Agents Featuring Dicarboxylato-Chelated Platinum
Komane, L. L., Mukaya, H. E., Neuse, E. W., & van Rensburg, C. E. J. (2007) · Journal of Inorganic and Organometallic Polymers and Materials · doi:10.1007/s10904-007-9175-7 · Cited by 26
Verschraegen, C. F., Kumagai, S., Davidson, R., Feig, B. W., Mansfield, P. F., Lee, S. J., MacLean, D. S., Hu, W., Khokhar, A. R., & Siddik, Z. H. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0481-3 · Cited by 26
Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs
Marr, A. K., Kurzman, I. D., & Vail, D. M. (2004) · American Journal of Veterinary Research · doi:10.2460/ajvr.2004.65.1474 · Cited by 24
MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal
Fedier, A., Poyet, C., Perucchini, D., Boulikas, T., & Fink, D. A. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200603000-00010 · Cited by 23
Wang, C., Gong, Y., Fan, N., Liu, S., Luo, S., Yu, J., & Huang, J. T. (2008) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2008.12.012 · Cited by 19
Oberoi, H. S., Nukolova, N. V., Zhao, Y., Cohen, S. M., Kabanov, A. V., & Bronich, T. K. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/905796 · Cited by 18
Self-citationNeuse, E. W., Mphephu, N., Netshifhefhe, H. M., & Johnson, M. T. (2002) · Polymers for Advanced Technologies · doi:10.1002/pat.241 · Cited by 16
Vokes, E. E., Gordon, G. S., Mauer, A. M., Rudin, C. M., Krauss, S. A., Szeto, L. L., Golomb, H. M., & Hoffman, P. C. (2000) · Clinical Lung Cancer · doi:10.3816/clc.2000.n.025 · Cited by 15
Farhat, F., Kattan, J., Ibrahim, K., Bitar, N., Haddad, N., Tamraz, S., Hatoum, H. A., & Shamseddine, A. I. (2010) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(10)70478-x · Cited by 14
Nanocapsules of Platinum Anticancer Drugs: Development Towards Therapeutic Use
Bryde, S., & de Kroon, A. I. P. M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.112 · Cited by 14
Phan, A. T., Takimoto, C. H. M., Adinin, R., Wood, L., Xiong, H. Q., Matsuno, K., Konno, S., Fujisawa, T., & Beeram, M. (2007) · Molecular Cancer Therapeutics · Cited by 11
Cited by
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
The side effects of platinum-based chemotherapy drugs: a review for chemists
Oun, R., Moussa, Y. E., & Wheate, N. J. (2018) · Dalton Transactions · doi:10.1039/c8dt00838h · Cited by 1,737
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Metadata
- Authors
- Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 65
- Issue
- 13-14
- Pages
- 1667-1685
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2091945030
- Cited by
- 396
- References
- 214
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.